Rejuvenation Technologies

Executive Summary

Rejuvenation Technologies is a preclinical biotechnology company pioneering an RNA-based platform to reverse cellular aging by extending telomeres. Founded in 2023 and headquartered in Palo Alto, the company leverages modified mRNA encapsulated in lipid nanoparticles to transiently express telomerase in targeted cells, thereby lengthening critically short telomeres. Its lead programs focus on age-related diseases driven by telomere dysfunction, including idiopathic pulmonary fibrosis (IPF), liver cirrhosis, and bone marrow failure syndromes. By addressing the root cause of cellular senescence, Rejuvenation aims to halt or reverse disease progression, offering a potentially transformative therapeutic approach for conditions with high unmet need. The platform's modularity allows for tissue-specific targeting via route of administration and capsid engineering, enabling a pipeline of indications.

Upcoming Catalysts (preview)

• Q4 2026Preclinical proof-of-concept data in IPF model60% success
• H1 2027Series A financing round70% success
• TBDIND submission for lead program30% success